Veeda Clinical Research acquires Heads, a European CRO
March 30, 2024
Source: drugdu
84
Veeda Clinical Research has acquired Heads, a privately held European CRO, which specialises in conducting clinical trials in oncology. Established in 2010, Heads has operational presence in 25 multiple strategically important locations across Europe, North America and Asia Pacific region. Veeda expands its reach to major geographies and adds capabilities of late-sta. ge clinical trial execution with strong focus on oncology with this acqusition
The acquisition provides Heads a strong operational platform and an opportunity to expand its expertise and capabilities to the Indian and South-East Asian markets.
With this acquisition, Veeda’s global pharma and biotech clients can now avail early to late-phase CRO services across Europe, US, and Asia Pacific.
During the integration phase, Heads will continue to offer uninterrupted support to client programs.
https://www.vspharma.in/veeda-clinical-research-acquires-heads-a-european-cro/
By editor
Copyright©2024 Ddu. All rights reserved.
Read more on
- Hand in hand with Merck and acquire shares from Zhongsheng Pharmaceutical! Lixin Pharmaceutical has become a dark horse in the development of new drugs, with a total pipeline BD transaction volume exceeding 28 billion yuan November 22, 2024
- Junshi Biotechnology introduces two cancer dual target fusion protein drugs November 22, 2024
- China Biopharmaceuticals announces signing equity investment and strategic cooperation agreement with Lixin Pharmaceutical November 22, 2024
- As the industry is going down, more and more pharmaceutical companies are seeking to “exit”? November 22, 2024
- Regeneron’s midlife crisis November 22, 2024
your submission has already been received.
OK
Subscribe
Please enter a valid Email address！
Submit
The most relevant industry news & insight will be sent to you every two weeks.
